Identification of tumor-specific MHC ligands through improved biochemical isolation and incorporation of machine learning

Mecklenbräuker,S.,Skoczylas,P.,Biernat,P.,Zaghla,B.,Krol-Jozaga,B.,Jasinski,M.,Murcia Pienkowski,V.,Sanecka-Duin,A.,Popp,O.,Szatanek,R.,Mertins,P.,Kaczmarczyk,J.,Blum,A.,Klatt,M. G.

DOI: https://doi.org/10.1101/2023.06.08.544182

2023-06-11

bioRxiv

Abstract:Isolation of MHC ligands and subsequent analysis by mass spectrometry is considered the gold standard for defining targets for TCR-T immunotherapies. However, as many targets of high tumor-specificity are only presented at low abundance on the cell surface of tumor cells, the efficient isolation of these peptides is crucial for their successful detection. Here, we demonstrate how different isolation strategies, which consider hydrophobicity and post-translational modifications, can improve the detection of MHC ligands, including cysteinylated MHC ligands from cancer germline antigens or point-mutated neoepitopes. Furthermore, we developed a novel MHC class I ligand prediction algorithm (ARDisplay-I) that outperforms the current state-of-the-art and facilitates the assignment of peptides to the correct MHC allele. The model has other applications, such as the identification of additional MHC ligands not detected from mass spectrometry or determining whether the MHC ligands can be presented on the cell surface via MHC alleles not included in the study. The implementation of these strategies can augment the development of T cell receptor-based therapies (i.a. TIL-derived T cells, genetically engineered T cells expressing tumor recognizing receptors or TCR-mimic antibodies) by facilitating the identification of novel immunotherapy targets and by enriching the resources available in the field of computational immunology.